## Jiangjiang Qin

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6491538/publications.pdf

Version: 2024-02-01

		101543	123424
121	4,493	36	61
papers	citations	h-index	g-index
125	125	125	5253
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The MDM2-p53 pathway revisited. Journal of Biomedical Research, 2013, 27, 254.	1.6	279
2	Ginsenosides as anticancer agents: In vitro and in vivo activities, structure–activity relationships, and molecular mechanisms of action. Frontiers in Pharmacology, 2012, 3, 25.	3.5	272
3	STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review. Journal of Experimental and Clinical Cancer Research, 2019, 38, 195.	8.6	249
4	Long non-coding RNAs towards precision medicine in gastric cancer: early diagnosis, treatment, and drug resistance. Molecular Cancer, 2020, 19, 96.	19.2	191
5	Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update. Drug Resistance Updates, 2020, 49, 100681.	14.4	154
6	PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy. Frontiers in Pharmacology, 2021, 12, 692574.	3.5	140
7	<i>Inula</i> sesquiterpenoids: structural diversity, cytotoxicity and anti-tumor activity. Expert Opinion on Investigational Drugs, 2014, 23, 317-345.	4.1	100
8	Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications. Medicinal Research Reviews, 2015, 35, 1220-1267.	10.5	93
9	NFAT as cancer target: Mission possible?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 297-311.	7.4	90
10	Japonicones A–D, bioactive dimeric sesquiterpenes from Inula japonica Thunb Bioorganic and Medicinal Chemistry Letters, 2009, 19, 710-713.	2.2	88
11	Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation. Journal of Medicinal Chemistry, 2021, 64, 8884-8915.	6.4	78
12	Natural Product Ginsenoside 25-OCH3-PPD Inhibits Breast Cancer Growth and Metastasis through Down-Regulating MDM2. PLoS ONE, 2012, 7, e41586.	2.5	73
13	The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models.  Nature Communications, 2014, 5, 5086.	12.8	70
14	New sesquiterpenes from Inula japonica Thunb. with their inhibitory activities against LPS-induced NO production in RAW264.7 macrophages. Tetrahedron, 2010, 66, 9379-9388.	1.9	69
15	Identification of a New Class of MDM2 Inhibitor That Inhibits Growth of Orthotopic Pancreatic Tumors in Mice. Gastroenterology, 2014, 147, 893-902.e2.	1.3	69
16	Dual roles and therapeutic potential of Keap1-Nrf2 pathway in pancreatic cancer: a systematic review. Cell Communication and Signaling, 2019, 17, 121.	6.5	68
17	Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine. Genes and Diseases, 2018, 5, 204-219.	3.4	66
18	Chemical Constituents of Plants from the Genus <i>Dracocephalum</i> . Chemistry and Biodiversity, 2010, 7, 1911-1929.	2.1	65

#	Article	IF	Citations
19	Sesquiterpene lactones from Inula falconeri, a plant endemic to the Himalayas, as potential anti-inflammatory agents. European Journal of Medicinal Chemistry, 2011, 46, 5408-5415.	5.5	64
20	Ainsliatrimers A and B, the First Two Guaianolide Trimers from <i>Ainsliaea fulvioides</i> Letters, 2008, 10, 5517-5520.	4.6	62
21	Neojaponicone A, a bioactive sesquiterpene lactone dimer with an unprecedented carbon skeleton from Inula japonica. Chemical Communications, 2011, 47, 1222-1224.	4.1	61
22	Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet?. Frontiers in Cell and Developmental Biology, 2020, 8, 233.	3.7	61
23	Sesquiterpenoids from <i>Inula lineariifolia</i> Inhibit Nitric Oxide Production. Journal of Natural Products, 2010, 73, 1117-1120.	3.0	58
24	Oral nano-delivery of anticancer ginsenoside 25-OCH3-PPD, a natural inhibitor of the MDM2 oncogene: Nanoparticle preparation, characterization, <i>in vitro</i> activity, and mechanisms of action. Oncotarget, 2015, 6, 21379-21394.	1.8	57
25	Natural Product MDM2 Inhibitors: Anticancer Activity and Mechanisms of Action. Current Medicinal Chemistry, 2012, 19, 5705-5725.	2.4	56
26	Targeting MDM2 for novel molecular therapy: Beyond oncology. Medicinal Research Reviews, 2020, 40, 856-880.	10.5	56
27	Identification of a new class of natural product MDM2 inhibitor:In vitroandin vivoanti-breast cancer activities and target validation. Oncotarget, 2015, 6, 2623-2640.	1.8	55
28	Phenylpropanoids and lignanoids from Euonymus acanthocarpus. Archives of Pharmacal Research, 2012, 35, 1739-1747.	6.3	54
29	Japonicones E–L, Dimeric Sesquiterpene Lactones from <i>Inula japonica</i> Thunb Planta Medica, 2010, 76, 278-283.	1.3	52
30	Pseudoguaianolides and Guaianolides from <i>Inula hupehensis</i> as Potential Anti-inflammatory Agents. Journal of Natural Products, 2011, 74, 1881-1887.	3.0	52
31	RYBP expression is associated with better survival of patients with hepatocellular carcinoma (HCC) and responsiveness to chemotherapy of HCC cells <i>in vitro</i> and <i>in vivo</i> Oncotarget, 2014, 5, 11604-11619.	1.8	46
32	Protein degradation technology: a strategicÂparadigmÂshift in drug discovery. Journal of Hematology and Oncology, 2021, 14, 138.	17.0	45
33	Japonicone A Suppresses Growth of Burkitt Lymphoma Cells through Its Effect on NF-κB. Clinical Cancer Research, 2013, 19, 2917-2928.	7.0	42
34	Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy. Cancer Research, 2018, 78, 5656-5667.	0.9	42
35	Selective cytotoxicity, inhibition of cell cycle progression, and induction of apoptosis in human breast cancer cells by sesquiterpenoids from Inula lineariifolia Turcz European Journal of Medicinal Chemistry, 2013, 68, 473-481.	5.5	41
36	The Role of Autophagy in Gastric Cancer Chemoresistance: Friend or Foe?. Frontiers in Cell and Developmental Biology, 2020, 8, 621428.	3.7	40

#	Article	IF	CITATIONS
37	Novel natural product therapeutics targeting both inflammation and cancer. Chinese Journal of Natural Medicines, 2017, 15, 401-416.	1.3	39
38	Cytotoxic Nitrogenated Azaphilones from the Deep-Sea-Derived Fungus <i>Chaetomium globosum</i> MP4-S01-7. Journal of Natural Products, 2020, 83, 1157-1166.	3.0	39
39	Highly efficient delivery of potent anticancer iminoquinone derivative by multilayer hydrogel cubes. Acta Biomaterialia, 2017, 58, 386-398.	8.3	37
40	MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53. Cancer Letters, 2019, 459, 156-167.	7.2	36
41	Japonicone A antagonizes the activity of TNF- $\hat{l}\pm$ by directly targeting this cytokine and selectively disrupting its interaction with TNF receptor-1. Biochemical Pharmacology, 2012, 84, 1482-1491.	4.4	35
42	Five new sesquiterpene lactones from Inula hupehensis. Archives of Pharmacal Research, 2013, 36, 1319-1325.	6.3	33
43	Japonicones Q–T, four new dimeric sesquiterpene lactones from Inula japonica Thunb Fìtoterapìâ, 2013, 84, 40-46.	2.2	33
44	miRNAs in Cancer Prevention and Treatment and as Molecular Targets for Natural Product Anticancer Agents. Current Cancer Drug Targets, 2013, 13, 519-541.	1.6	33
45	A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance. Genes and Diseases, 2019, 6, 419-430.	3.4	33
46	JKA97, a Novel Benzylidene Analog of Harmine, Exerts Anti-Cancer Effects by Inducing G1 Arrest, Apoptosis, and p53-Independent Up-Regulation of p21. PLoS ONE, 2012, 7, e34303.	2.5	32
47	Oral delivery of anti-MDM2 inhibitor SP141-loaded FcRn-targeted nanoparticles to treat breast cancer and metastasis. Journal of Controlled Release, 2016, 237, 101-114.	9.9	31
48	Blumeaenes A–J, Sesquiterpenoid Esters from <i>Blumea balsamifera</i> with NO Inhibitory Activity. Planta Medica, 2010, 76, 897-902.	1.3	28
49	Lineariifolianoids A–D, rare unsymmetrical sesquiterpenoid dimers comprised of xanthane and guaiane framework units from Inula lineariifolia. RSC Advances, 2012, 2, 1307.	3.6	28
50	Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and Androgen. Frontiers in Pharmacology, 2017, 8, 917.	3.5	28
51	Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA. Oncotarget, 2015, 6, 33106-33119.	1.8	28
52	Sesquiterpenoids from <i>Inula racemosa </i> Hook. f. Inhibit Nitric Oxide Production. Planta Medica, 2012, 78, 166-171.	1.3	27
53	Prevention of prostate cancer by natural product MDM2 inhibitor GS25: in vitro and in vivo activities and molecular mechanisms. Carcinogenesis, 2018, 39, 1026-1036.	2.8	27
54	Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy. Oncotarget, 2016, 7, 32566-32578.	1.8	27

#	Article	IF	CITATIONS
55	RYBP predicts survival of patients with non-small cell lung cancer and regulates tumor cell growth and the response to chemotherapy. Cancer Letters, 2015, 369, 386-395.	7.2	26
56	Aspeterreurone A, a Cytotoxic Dihydrobenzofuran–Phenyl Acrylate Hybrid from the Deep-Sea-Derived Fungus <i>Aspergillus terreus</i> CC-S06-18. Journal of Natural Products, 2020, 83, 1998-2003.	3.0	26
57	Sesquiterpene Lactones from Inula hupehensis Inhibit Nitric Oxide Production in RAW264.7 Macrophages. Planta Medica, 2012, 78, 1002-1009.	1.3	25
58	Targeting $\hat{l}^2$ -Catenin Signaling by Natural Products for Cancer Prevention and Therapy. Frontiers in Pharmacology, 2020, 11, 984.	3.5	25
59	Chemical Constituents from Aphanamixis grandifolia. Chemistry of Natural Compounds, 2013, 49, 486-492.	0.8	24
60	Bioactive eudesmane and germacrane derivatives from Inula wissmanniana HandMazz Phytochemistry, 2013, 96, 214-222.	2.9	24
61	Targeting MDMX for Cancer Therapy: Rationale, Strategies, and Challenges. Frontiers in Oncology, 2020, 10, 1389.	2.8	23
62	Antimicrobial Peptide Reverses ABCB1-Mediated Chemotherapeutic Drug Resistance. Frontiers in Pharmacology, 2020, 11, 1208.	3.5	23
63	Identification of lineariifolianoid A as a novel dual NFAT1 and MDM2 inhibitor for human cancer therapy. Journal of Biomedical Research, 2016, 30, 322-33.	1.6	23
64	A new triterpenoid from Brucea javanica. Archives of Pharmacal Research, 2009, 32, 661-666.	6.3	22
65	A new ent-kaurane type diterpenoid glycoside from Inula japonica Thunb Archives of Pharmacal Research, 2009, 32, 1369-1372.	6.3	22
66	2,3-Seco- and 3,4-seco-tirucallane triterpenoid derivatives from the stems of Aphanamixis grandifolia Blume. Phytochemistry, 2012, 80, 148-155.	2.9	22
67	Inhibiting $\hat{I}^2$ -Catenin by $\hat{I}^2$ -Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy. Frontiers in Pharmacology, 2018, 9, 5.	3.5	21
68	Chemical Constituents of Plants from the Genus <i>Geum</i> . Chemistry and Biodiversity, 2011, 8, 203-222.	2.1	20
69	Experimental Therapy of Advanced Breast Cancer: Targeting NFAT1–MDM2–p53 Pathway. Progress in Molecular Biology and Translational Science, 2017, 151, 195-216.	1.7	20
70	Phytane and neoclerodane diterpenes from the aerial parts of Inula nervosa Wall Biochemical Systematics and Ecology, 2011, 39, 700-703.	1.3	19
71	Terphenyllin Suppresses Orthotopic Pancreatic Tumor Growth and Prevents Metastasis in Mice. Frontiers in Pharmacology, 2020, $11$ , 457.	3.5	19
72	Chemical Constituents of Plants from the Genus <i>Euonymus</i> . Chemistry and Biodiversity, 2012, 9, 1055-1076.	2.1	18

#	Article	IF	Citations
73	Four New Sesquiterpenoids from the Roots of Incarvillea arguta and Their Inhibitory Activities against Lipopolysaccharide-Induced Nitric Oxide Production. Chemical and Pharmaceutical Bulletin, 2010, 58, 1263-1266.	1.3	17
74	Taraxasterane-Type Triterpene and Neolignans from <i>Geum japonicum </i> Thunb. var. <i>chinense </i> F. Bolle. Planta Medica, 2011, 77, 2061-2065.	1.3	17
75	Synthesis, Characterization, Cellular Uptake, and In Vitro Anticancer Activity of Fullerenol-Doxorubicin Conjugates. Frontiers in Pharmacology, 2020, 11, 598155.	3.5	17
76	Three New Phenylpropanoids from <i>Inula nervosa</i> <scp>Wall</scp> Helvetica Chimica Acta, 2010, 93, 1418-1421.	1.6	16
77	Identification of an Immune Gene-Associated Prognostic Signature and Its Association With a Poor Prognosis in Gastric Cancer Patients. Frontiers in Oncology, 2020, 10, 629909.	2.8	16
78	New glycosides from Dracocephalum tanguticum maxim. Archives of Pharmacal Research, 2011, 34, 2015-2020.	6.3	15
79	Targeting E2 ubiquitin-conjugating enzyme UbcH5c by small molecule inhibitor suppresses pancreatic cancer growth and metastasis. Molecular Cancer, 2022, 21, 70.	19.2	15
80	Monoterpenes and other chemical constituents from the aerial parts of Inula japonica. Chemistry of Natural Compounds, 2011, 47, 303-305.	0.8	14
81	Chemical Constituents of Plants from the Genus <i>Incarvillea</i> . Chemistry and Biodiversity, 2009, 6, 818-826.	2.1	13
82	Terpenoids from Inula sericophylla Franch. and their chemotaxonomic significance. Biochemical Systematics and Ecology, 2012, 42, 75-78.	1.3	13
83	Two New Cytotoxic Biphenyls from the Roots ofIncarvillea arguta. Helvetica Chimica Acta, 2009, 92, 491-494.	1.6	12
84	Hookerolides A–D, the first naturally occurring C17-pseudoguaianolides from Inula hookeri. Tetrahedron Letters, 2013, 54, 1943-1946.	1.4	12
85	Development and validation of a rapid HPLC method for quantitation of SPâ€141, a novel pyrido[b]indole anticancer agent, and an initial pharmacokinetic study in mice. Biomedical Chromatography, 2015, 29, 654-663.	1.7	12
86	p-MEK expression predicts prognosis of patients with adenocarcinoma of esophagogastric junction (AEG) and plays a role in anti-AEG efficacy of Huaier. Pharmacological Research, 2021, 165, 105411.	7.1	12
87	Aphanamgrandiol A, a new triterpenoid with a unique carbon skeleton from Aphanamixis grandifolia. Fìtoterapìâ, 2013, 86, 217-221.	2.2	11
88	The E2 ubiquitin-conjugating enzyme UbcH5c: an emerging target in cancer and immune disorders. Drug Discovery Today, 2020, 25, 1988-1997.	6.4	11
89	Integrated Bioinformatics Analysis Reveals Key Candidate Genes and Pathways Associated With Clinical Outcome in Hepatocellular Carcinoma. Frontiers in Genetics, 2020, 11, 814.	2.3	11
90	Preclinical pharmacology of novel indolecarboxamide ML-970, an investigative anticancer agent. Cancer Chemotherapy and Pharmacology, 2012, 69, 1423-1431.	2.3	9

#	Article	IF	CITATIONS
91	Identification and structural characterization of dimeric sesquiterpene lactones in ⟨i⟩Inula japonica⟨ i⟩ Thunb. by highâ€performance liquid chromatography electrospray ionization with multiâ€stage mass spectrometry. Rapid Communications in Mass Spectrometry, 2013, 27, 2159-2169.	1.5	9
92	Anthranilic acid derivatives from Inula japonica. Chinese Chemical Letters, 2008, 19, 556-558.	9.0	8
93	Chemical constituents from Verbena officinalis. Chemistry of Natural Compounds, 2011, 47, 319-320.	0.8	8
94	Identification of the ZAK-MKK4-JNK-TGFβ Signaling Pathway as a Molecular Target for Novel Synthetic Iminoquinone Anticancer Compound BA-TPQ. Current Cancer Drug Targets, 2013, 13, 651-660.	1.6	8
95	Three New Neolignans and One New Phenylpropanoid from the Leaves and Stems of <i>Toona ciliata</i> var. <i>pubescens</i> Helvetica Chimica Acta, 2011, 94, 1685-1691.	1.6	7
96	Identification of a DNA Methylation-Driven Genes-Based Prognostic Model and Drug Targets in Breast Cancer: In silico Screening of Therapeutic Compounds and in vitro Characterization. Frontiers in Immunology, 2021, 12, 761326.	4.8	7
97	A new nor-sesquiterpene lactone from Ainsliaea fulvioides. Chinese Chemical Letters, 2009, 20, 586-588.	9.0	6
98	Norlignans and Phenylpropanoids from Metasequoia glyptostroboidesHu et Cheng. Helvetica Chimica Acta, 2012, 95, 606-612.	1.6	6
99	Chemical constiuents of Euonymus acanthocarpus. Chemistry of Natural Compounds, 2013, 49, 383-387.	0.8	6
100	A quantitative LC-MS/MS method for determination of SP-141, a novel pyrido[b]indole anticancer agent, and its application to a mouse PK study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 969, 235-240.	2.3	6
101	Chemical constituents from wetland soil fungus Penicillium oxalicum GY1. Fìtoterapìâ, 2020, 142, 104530.	2.2	6
102	Two new monoterpene alkaloid derivatives from the roots of Incarvillea arguta. Archives of Pharmacal Research, 2011, 34, 199-202.	6.3	5
103	Is CDK9 a promising target for both primary and metastatic osteosarcoma?. EBioMedicine, 2019, 40, 27-28.	6.1	4
104	Structure elucidation of a novel cyclic tripeptide from the marine-derived fungus <i>Aspergillus ochraceopetaliformis</i> DSW-2. Natural Product Research, 2022, 36, 3572-3578.	1.8	4
105	Argutalactone, an unprecedented sesquiterpenoid lactone with a 6/5/7 tricyclic system from <i>Incarvillea arguta</i> I>. Journal of Asian Natural Products Research, 2012, 14, 496-502.	1.4	3
106	The role of miRNAs in MDMXâ€p53 interplay. Journal of Evidence-Based Medicine, 2021, 14, 152-160.	1.8	3
107	Integrative analysis reveals clinically relevant molecular fingerprints in pancreatic cancer.  Molecular Therapy - Nucleic Acids, 2021, 26, 11-21.	5.1	3
108	Sesquiterpene lactones from Inula helianthus-aquatica. Zhongguo Zhongyao Zazhi, 2012, 37, 1586-9.	0.1	3

#	Article	IF	CITATIONS
109	Biodegradable iron oxide nanoparticles for intraoperative parathyroid gland imaging in thyroidectomy. , 2022, $1,\dots$		3
110	Chemical constituents of the aerial parts of Aconitum kongboense. Chemistry of Natural Compounds, 2011, 47, 854-855.	0.8	2
111	Development and validation of an HPLC-MS/MS analytical method for quantitative analysis of TCBA-TPQ, a novel anticancer makaluvamine analog, and application in a pharmacokinetic study in rats. Chinese Journal of Natural Medicines, 2015, 13, 554-560.	1.3	2
112	Sesquiterpene lactones from Inula helianthus-aquatica. Zhongguo Zhongyao Zazhi, 2012, , .	0.1	2
113	Abstract 2434: The anticancer activity of Japonicone A is mediated by inhibiting NFAT1-MDM2 pathway., 2015, , .		0
114	Abstract 5266: RYBP expression predicts survival of patients with hepatocellular carcinoma, and regulates response to chemotherapy. , $2015$ , , .		0
115	Abstract 2433: A novel MDM2 inhibitor suppresses breast cancer growth and metastasis., 2015,,.		0
116	Abstract 4867: Treating hepatocellular carcinoma metastasis and overcoming chemoresistance through inhibiting the MDM2 oncogene. , 2018, , .		0
117	Abstract 4863: Targeting the NFAT1-MDM2-MDMX network for prostate cancer therapy. , 2018, , .		0
118	Abstract 3858: Inflammation and oncogene in hepatocellular carcinoma: Clinical relevance and experimental targeted therapy. , 2019, , .		0
119	Editorial: Alcohol Consumption and Liver Diseases: From Pathology to Phytotherapy. Frontiers in Pharmacology, 2022, 13, 848334.	3.5	0
120	Abstract 5017: A single-cell atlas of tumor microenvironment defines the continuum of gastric adenocarcinoma tumorigenesis and progression. Cancer Research, 2022, 82, 5017-5017.	0.9	0
121	Abstract 5072: A novel antibody drug conjugateengineered for chromosome instable gastric cancer. Cancer Research, 2022, 82, 5072-5072.	0.9	O